cpg methyltransferase Search Results


m sssi  (New England Biolabs)
96
New England Biolabs m sssi
M Sssi, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/m sssi/product/New England Biolabs
Average 96 stars, based on 1 article reviews
m sssi - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
vitro cpg methylated dna with sssi cpg methyltransferase  (New England Biolabs)
96
New England Biolabs vitro cpg methylated dna with sssi cpg methyltransferase
Vitro Cpg Methylated Dna With Sssi Cpg Methyltransferase, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vitro cpg methylated dna with sssi cpg methyltransferase/product/New England Biolabs
Average 96 stars, based on 1 article reviews
vitro cpg methylated dna with sssi cpg methyltransferase - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
cpg methyltransferase  (CEM Corporation)
90
CEM Corporation cpg methyltransferase
Cpg Methyltransferase, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpg methyltransferase/product/CEM Corporation
Average 90 stars, based on 1 article reviews
cpg methyltransferase - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cpg methyltransferase m. sss i  (INFINIUM Inc)
90
INFINIUM Inc cpg methyltransferase m. sss i
Tissues were obtained and processed as described in Materials and Methods. Tissues were processed and nuclei were either left untreated or were treated with the M.SssI <t>methyltransferase</t> enzyme. Endogenously methylated loci are unable to be interrogated (as illustrated). Following bisulfite conversion and HM450 analyses, untreated (endogenous) DNA methylation values from each sample were subtracted from respective enzyme-treated (exogenous) DNA methylation values, revealing chromatin accessibility changes.
Cpg Methyltransferase M. Sss I, supplied by INFINIUM Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpg methyltransferase m. sss i/product/INFINIUM Inc
Average 90 stars, based on 1 article reviews
cpg methyltransferase m. sss i - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cpg methyltransferase m.sssi  (Illumina Inc)
90
Illumina Inc cpg methyltransferase m.sssi
Majority of probes demethylated by 5-Aza-CdR are inaccessible to CpG <t>methyltransferase</t> M.SssI after 5-Aza-CdR treatment. ( A ) Schematic of the Acce SssI ble assay: after nuclei are treated with M.Sss1 (or a no-enzyme treatment control), DNA is extracted, bisulfite converted and assayed on the Illumina methylation 450 k beadchip. Endogenous DNA methylation status is obtained from the no-enzyme control (green indicating unmethylated and red methylated), and information on chromatin state for unmethylated probes is attained from the accessibility of the M.SssI methyltransferase to CpG dinucleotides (scaled from yellow to blue, with yellow as inaccessible and blue as highly accessible). ( B ) Kernel density scatter plot of delta-methylation (methylation in treated minus methylation in control) versus delta-accessibility (accessibility in treated minus accessibility in control) shows that majority of demethylated loci do not gain accessibility. Groups a and b are events that depict changes in chromatin accessibility independent of DNA methylation, whereas group c depicts regions that gain accessibility on DNA demethylation. ( C ) Bar graph depicting percentage of demethylated promoter- (9719), body- (1205) and enhancer-associated (28 348) probes that gain accessibility or remain inaccessible on demethylation. ( D ) Venn diagram of all promoter regions that are demethylated post-5-Aza-CdR treatment in HCT116 as well with those that gain accessibility. Results show that ∼90% of regions require demethylation to gain accessibility. ( E ) Volcano plot of genes whose promoters gain accessibility after treatment shows that most of these regions gain expression.
Cpg Methyltransferase M.Sssi, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpg methyltransferase m.sssi/product/Illumina Inc
Average 90 stars, based on 1 article reviews
cpg methyltransferase m.sssi - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
m. sssl enzyme (cpg methyltransferase)  (Verlag GmbH)
90
Verlag GmbH m. sssl enzyme (cpg methyltransferase)
Majority of probes demethylated by 5-Aza-CdR are inaccessible to CpG <t>methyltransferase</t> M.SssI after 5-Aza-CdR treatment. ( A ) Schematic of the Acce SssI ble assay: after nuclei are treated with M.Sss1 (or a no-enzyme treatment control), DNA is extracted, bisulfite converted and assayed on the Illumina methylation 450 k beadchip. Endogenous DNA methylation status is obtained from the no-enzyme control (green indicating unmethylated and red methylated), and information on chromatin state for unmethylated probes is attained from the accessibility of the M.SssI methyltransferase to CpG dinucleotides (scaled from yellow to blue, with yellow as inaccessible and blue as highly accessible). ( B ) Kernel density scatter plot of delta-methylation (methylation in treated minus methylation in control) versus delta-accessibility (accessibility in treated minus accessibility in control) shows that majority of demethylated loci do not gain accessibility. Groups a and b are events that depict changes in chromatin accessibility independent of DNA methylation, whereas group c depicts regions that gain accessibility on DNA demethylation. ( C ) Bar graph depicting percentage of demethylated promoter- (9719), body- (1205) and enhancer-associated (28 348) probes that gain accessibility or remain inaccessible on demethylation. ( D ) Venn diagram of all promoter regions that are demethylated post-5-Aza-CdR treatment in HCT116 as well with those that gain accessibility. Results show that ∼90% of regions require demethylation to gain accessibility. ( E ) Volcano plot of genes whose promoters gain accessibility after treatment shows that most of these regions gain expression.
M. Sssl Enzyme (Cpg Methyltransferase), supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/m. sssl enzyme (cpg methyltransferase)/product/Verlag GmbH
Average 90 stars, based on 1 article reviews
m. sssl enzyme (cpg methyltransferase) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Tissues were obtained and processed as described in Materials and Methods. Tissues were processed and nuclei were either left untreated or were treated with the M.SssI methyltransferase enzyme. Endogenously methylated loci are unable to be interrogated (as illustrated). Following bisulfite conversion and HM450 analyses, untreated (endogenous) DNA methylation values from each sample were subtracted from respective enzyme-treated (exogenous) DNA methylation values, revealing chromatin accessibility changes.

Journal: Cancer research

Article Title: Identification of DNA methylation-independent epigenetic events underlying clear cell renal cell carcinoma

doi: 10.1158/0008-5472.CAN-15-2622

Figure Lengend Snippet: Tissues were obtained and processed as described in Materials and Methods. Tissues were processed and nuclei were either left untreated or were treated with the M.SssI methyltransferase enzyme. Endogenously methylated loci are unable to be interrogated (as illustrated). Following bisulfite conversion and HM450 analyses, untreated (endogenous) DNA methylation values from each sample were subtracted from respective enzyme-treated (exogenous) DNA methylation values, revealing chromatin accessibility changes.

Article Snippet: Acce SssI ble is rapid and cost-effective, only requiring 20 mg of tissue, the Infinium HumanMethylation450 BeadChip platform, and the CpG methyltransferase M. Sss I.

Techniques: Methylation, DNA Methylation Assay

Majority of probes demethylated by 5-Aza-CdR are inaccessible to CpG methyltransferase M.SssI after 5-Aza-CdR treatment. ( A ) Schematic of the Acce SssI ble assay: after nuclei are treated with M.Sss1 (or a no-enzyme treatment control), DNA is extracted, bisulfite converted and assayed on the Illumina methylation 450 k beadchip. Endogenous DNA methylation status is obtained from the no-enzyme control (green indicating unmethylated and red methylated), and information on chromatin state for unmethylated probes is attained from the accessibility of the M.SssI methyltransferase to CpG dinucleotides (scaled from yellow to blue, with yellow as inaccessible and blue as highly accessible). ( B ) Kernel density scatter plot of delta-methylation (methylation in treated minus methylation in control) versus delta-accessibility (accessibility in treated minus accessibility in control) shows that majority of demethylated loci do not gain accessibility. Groups a and b are events that depict changes in chromatin accessibility independent of DNA methylation, whereas group c depicts regions that gain accessibility on DNA demethylation. ( C ) Bar graph depicting percentage of demethylated promoter- (9719), body- (1205) and enhancer-associated (28 348) probes that gain accessibility or remain inaccessible on demethylation. ( D ) Venn diagram of all promoter regions that are demethylated post-5-Aza-CdR treatment in HCT116 as well with those that gain accessibility. Results show that ∼90% of regions require demethylation to gain accessibility. ( E ) Volcano plot of genes whose promoters gain accessibility after treatment shows that most of these regions gain expression.

Journal: Nucleic Acids Research

Article Title: Functional DNA demethylation is accompanied by chromatin accessibility

doi: 10.1093/nar/gkt077

Figure Lengend Snippet: Majority of probes demethylated by 5-Aza-CdR are inaccessible to CpG methyltransferase M.SssI after 5-Aza-CdR treatment. ( A ) Schematic of the Acce SssI ble assay: after nuclei are treated with M.Sss1 (or a no-enzyme treatment control), DNA is extracted, bisulfite converted and assayed on the Illumina methylation 450 k beadchip. Endogenous DNA methylation status is obtained from the no-enzyme control (green indicating unmethylated and red methylated), and information on chromatin state for unmethylated probes is attained from the accessibility of the M.SssI methyltransferase to CpG dinucleotides (scaled from yellow to blue, with yellow as inaccessible and blue as highly accessible). ( B ) Kernel density scatter plot of delta-methylation (methylation in treated minus methylation in control) versus delta-accessibility (accessibility in treated minus accessibility in control) shows that majority of demethylated loci do not gain accessibility. Groups a and b are events that depict changes in chromatin accessibility independent of DNA methylation, whereas group c depicts regions that gain accessibility on DNA demethylation. ( C ) Bar graph depicting percentage of demethylated promoter- (9719), body- (1205) and enhancer-associated (28 348) probes that gain accessibility or remain inaccessible on demethylation. ( D ) Venn diagram of all promoter regions that are demethylated post-5-Aza-CdR treatment in HCT116 as well with those that gain accessibility. Results show that ∼90% of regions require demethylation to gain accessibility. ( E ) Volcano plot of genes whose promoters gain accessibility after treatment shows that most of these regions gain expression.

Article Snippet: We study this phenomenon globally using a novel assay that we have devised, using the CpG methyltransferase M.SssI ( ) to infer chromatin accessibility using an Illumina methylation array.

Techniques: Control, Methylation, DNA Methylation Assay, Expressing